Hepatocyte mARC1 promotes fatty liver disease

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) has a prevalence of ∼25% worldwide, with significant public health consequences yet few effective treatments. Human genetics can help elucidate novel biology and identify targets for new therapeutics. Genetic variants in mitochondrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Lara C., Chen, Lingyan, Hameed, L. Shahul, Kitchen, Robert R., Maroteau, Cyrielle, Nagarajan, Shilpa R., Norlin, Jenny, Daly, Charlotte E., Szczerbinska, Iwona, Hjuler, Sara Toftegaard, Patel, Rahul, Livingstone, Eilidh J., Durrant, Tom N., Wondimu, Elisabeth, BasuRay, Soumik, Chandran, Anandhakumar, Lee, Wan-Hung, Hu, Sile, Gilboa, Barak, Grandi, Megan E., Toledo, Enrique M., Erikat, Abdullah H.A., Hodson, Leanne, Haynes, William G., Pursell, Natalie W., Coppieters, Ken, Fleckner, Jan, Howson, Joanna M.M., Andersen, Birgitte, Ruby, Maxwell A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133763/
https://www.ncbi.nlm.nih.gov/pubmed/37122688
http://dx.doi.org/10.1016/j.jhepr.2023.100693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133763/
https://www.ncbi.nlm.nih.gov/pubmed/37122688
http://dx.doi.org/10.1016/j.jhepr.2023.100693

Ejemplares similares